For small chemical entities, we start with a profound physical, chemical, and biopharmaceutical characterization and develop novel and innovative methods to gain further insight into their properties. Based on these thorough studies, we apply innovative approaches with a focus on salt engineering including the synthesis and application of tailor-made counterions, development of optimized formulations and characterization, thereof (e.g. on-line investigation of crystallization) and pharmacokinetic correlation.
Another question we address in this research branch is the drug delivery of therpeutic gases, a fascinating yet rather unexplored class of new chemical entities.
We develop bioresponsive drug release systems, releasing drugs as a result of an external, biochemical stimulus. The concept is quite striking: Consider an inflamed tissue. During inflammation, a suite of proteases is upregulated at this site. The bioresponsive drug delivery carrier is designed to disintegrate at sites of elevated protease activity and this is why the drug is preferentially unloaded at the seat of the inflammation. The concept is also used to respond to bacterial proteases for site directed unload of antibiotics and for the design of advanced diagnostics.
We redesign biologics for advanced pharmaceutical outcome. By using an expanded genetic code we clone, express, isolate, purify, and analyze biologics with unnatural amino acids (AA). These AA are always located at the same site within the molecule and carry functional groups which are normally not present in proteins. Thereby, covalent decoration of this functional group can be in a strictly site directed manner, addressing the disadvantage of current approaches which ultimately lead to heterogenous product outcome. Our current portfolio of biologics include anti-infective peptides, growth factors, cytokines, or fluorescent proteins and covalently bound binding partners stretch from small molecules, to sugars, various polymers, biomaterials, or cell surfaces, and others.